A large‐scale, multicenter characterization of BRAF G469V/A‐mutant non‐small cell lung cancer

Abstract Background Mutated BRAF is identified in 1%–5% non‐small cell lung cancer (NSCLC) patients, with non‐V600 mutations accounting for 50%–70% of these. The most common non‐V600 mutation is BRAF G469V/A. Currently, there are no targeted therapies available for non‐V600 mutated patients. A recen...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Han Wu, Jian Feng, Shun Lu, Jia Huang
Format:	Article
Language:	English
Published:	Wiley 2024-05-01
Subjects:	BRAF G469 gefitinib non‐small cell lung cancer (NSCLC) targeted therapy
Online Access:	https://doi.org/10.1002/cam4.7305